In clinical trials, diarrhea is a common side effect, occurring in approximately 30% of patients taking Wegovy (semaglutide 2.4 mg) and 19-23% of patients taking Zepbound (tirzepatide), according to FDA prescribing information
If these enrollees leave, the Medicaid population would likely (once again) skew older and sicker, likely worsening the utilization, acuity, and MLR challenges that health plans have grappled with in recent years
Lv et al., 2016), the general pathway by which miRNAs modulate GSH level
for example, a new function-based classification is being applied in some research fields (Mosser and Edwards, 2008)
It far exceeds other GLP-1 products, including Semaglutide (Wegovy, Ozempic, & Rybelsius)
[1] [2] It has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) at the time of writing